Cross-cultural Adaptation and Linguistic Validation of the Korean Version of the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale

Cholhee Park,1 Youn-Woo Lee,1 Duck Mi Yoon,2 Do Wan Kim,3 Da Jeong Nam,4 and Do-Hyeong Kim2

1Department of Anesthesiology and Pain Medicine, Gangnam Severance Hospital, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul; 2Department of Anesthesiology and Pain Medicine, Severance Hospital, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul; 3Department of Anesthesiology and Pain Medicine, Ajou University Hospital, College of Medicine, Ajou University, Suwon; 4Department of Anesthesiology and Pain Medicine, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea

Received: 5 February 2015 Accepted: 28 May 2015

Address for Correspondence:
Do-Hyeong Kim, MD
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea
Tel: +82.2-2228-5770, Fax: +82.2-2228-7897
E-mail: breadfans@yuhs.ac

INTRODUCTION

Neuropathic pain is defined as “a pain caused by a lesion or disease of the somatosensory system” according to the International Association for the Study of Pain (1). Neuropathic pain is diagnosed by an expert physician based on a detailed clinical history, physical exploration, and clinical judgment as well as by electrophysiological examinations and imaging studies as needed (2).

However, it is difficult to distinguish neuropathic pain from other types of pain and to diagnose the lesion or disease causing the pain (2). Moreover, an accurate diagnosis of neuropathic pain requires training and experience, which is time-consuming. Early identification of neuropathic pain in primary and specialty care settings would avoid unnecessary delays in the improvement of symptoms (3). Therefore, easy-to-screen questionnaires for neuropathic pain in patients with chronic pain would be of great clinical benefit.

The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale, a screening questionnaire for identifying patients with neuropathic pain, was developed to identify patients with neuropathic mechanisms dominating their pain experience (4). The LANSS pain scale is comprised of 7 items divided into 5 symptoms and 2 signs. It is concordant of clinical diagnosis with a sensitivity and specificity of 83% and 87%, respectively, and a score of at least 12 of 24 points (4). The original English version of the LANSS pain scale has been translated and validated in Turkish (5), Spanish (6), Swedish (7), Brazilian Portuguese (8), Portuguese (9), and Chinese Mandarin (10). However, no neuropathic pain questionnaire including the LANSS has yet been established in Korea.

Although these screening tools are based on descriptors, their linguistic adaptation and validation into different languages are feasible and this ensures their reliability and validity in languages other than those in which they were initially developed (11). As cross-border and cross-cultural studies continue to increase, there is a greater need for linguistic validation across a variety of societies. In order to use questionnaires in areas with different languages and cultures, not only translation into new languages is required, there is also a need for adaptation of questionnaires.

Distinction between neuropathic pain and nociceptive pain helps facilitate appropriate management of pain; however, diagnosis of neuropathic pain remains a challenge. The aim of this study was to develop a Korean version of the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale and assess its reliability and validity. The translation and cross-cultural adaptation of the original LANSS pain scale into Korean was established according to the published guidelines. The Korean version of the LANSS pain scale was applied to a total of 213 patients who were expertly diagnosed with neuropathic (n = 113) or nociceptive pain (n = 100). The Korean version of the scale had good reliability (Cronbach’s α coefficient = 0.815, Guttman split-half coefficient = 0.800). The area under the receiver operating characteristic curve was 0.928 with a 95% confidence interval of 0.885-0.959 (P < 0.001), suggesting good discriminate value. With a cut-off score ≥ 12, sensitivity was 72.6%, specificity was 98.0%, and the positive and negative predictive values were 98% and 76%, respectively. The Korean version of the LANSS pain scale is a useful, reliable, and valid instrument for screening neuropathic pain from nociceptive pain.

Keywords: Neuralgia; Symptom Assessment; Validation Studies
to suit regional characteristics. The aim of this study was to translate and adapt the LANSS pain scale into Korean and to investigate the reliability and validity of the Korean version of the LANSS (K-LANSS) pain scale.

**MATERIALS AND METHODS**

This study had 2 stages. First, the English version of the LANSS was translated into Korean, and the K-LANSS was developed through cross-cultural adaptation. In the second stage, the reliability and validity of the K-LANSS were examined in patients visiting the outpatient department for pain management.

**Development of the K-LANSS**

The translation and cross-cultural adaptation process of the LANSS pain scale was carried out based on the guidelines put forth by Beaton et al. and Guillemin et al. (Fig. 1) (12, 13). Two native Korean translators fluent in both English and Korean each completed a separate forward translation from English to Korean. One forward translator was an informed pain physician and the other was an uninformed non-physician. The two versions were synthesized into a single Korean version by the two translators. This synthesized version of the Korean LANSS was then given to two independent native English-speaking translators fluent in Korean, for back translation into English. One back translator was an uninformed pain physician and the other was an uninformed non-physician. An expert committee composed of forward translators, back translators, and 5 pain specialists reviewed the forward translation, the synthesized version of the Korean LANSS, the back translation, and the original version of the LANSS. This expert committee produced the pre-final version of the K-LANSS focusing on linguistic and cultural differences. Discrepancies were resolved by consensus to achieve conceptual equivalence with the original questionnaire. The pre-final version of the K-LANSS was field-tested on 20 patients. After completion of the questionnaire, each question was discussed with the patient to determine whether all items had been fully understood and to understand whether the patients had any problems with the formulation. The final version of the K-LANSS was created reflecting the problems identified and was verified by the committee (Appendix 1).

The K-LANSS pain scale is based on an analysis of the sensory description and bedside examination of dysfunction. It is comprised of 5 symptoms and 2 clinical examinations. The first part consists of 5 dichotomous questions asking the patient what kind of pain he or she experienced in the last week. The second part consists of a sensitivity examination, through which the health professional explores skin sensitivity, comparing the painful area with a non-painful contralateral or adjacent area. The presence of allodynia and altered pinprick perception threshold are explored. The possible scores range from 0 to 24.

**Clinical study for reliability and validity of the K-LANSS**

In order to measure reliability and validity of the K-LANSS, an observational study was designed to be carried out under the normal conditions of clinical practice. Patients who visited the outpatient department in 1 of 2 tertiary university hospitals for pain management between June 2014 and December 2014 were

![Fig. 1. Translation and adaptation process of the original Leeds Assessment of Neuropathic Symptoms and Signs pain scale.](http://dx.doi.org/10.3346/jkms.2015.30.9.1334)
screened by the following criteria. The inclusion criteria were as follows: age of 20 yr or older; 11-point numeric rating scale (NRS) pain score ≥ 4; and able to speak and write Korean. The exclusion criteria were as follows: uncertain diagnosis; mixed pain presentation, visceral pain, or fibromyalgia; depression, alcoholism, or drug abuse; inability to understand or read the questionnaire; and visual impairment.

Differential diagnosis of patients regarding neuropathic or nociceptive pain was initially made by 2 independent pain specialists in each separate hospital. The diagnosis was based on medical history, detailed clinical examination, neuroimaging, electrophysiological studies and laboratory tests (14). Neuropathic pain was determined by clinical and laboratorial tests, which included identification of abnormal sensory perception, such as postherpetic neuralgia or peripheral neuropathy. Nociceptive pain was diagnosed by the clinical and/or laboratorial evidence of nonneuronal tissue damage, such as myofascial pain syndrome, and/or with normal electrophysiological studies. The patient was included in the clinical study only if 2 independent pain specialists concurred in the diagnosis of pain type. Subsequently, another researcher blinded to the pain classification of the participants, had the subjects answer the K-LANSS and collected data about the patients pain such as their NRS pain score and duration of pain and also about their socio-demographic characteristics such as age, gender, occupation, education level, and routine medical information.

Statistical analysis
Generally, a sample size of at least 50 patients is recommended for a reliability test. For an exploratory factor analysis, 7 patients per item and at least 100 patients are recommended (15). Thus, a sample size of at least 100 patients in each group was required. Descriptive statistics were used to describe demographic characteristics. The normality of the data distribution was assessed using the Kolmogorov-Smirnov test. Comparisons were made with the independent t-test, Mann-Whitney U test, chi-square test, and Fisher’s exact test as appropriate. Reliability was assessed by analysis of internal consistency and exploratory factor analysis. Internal consistency measures the consistency of each item on the same questionnaire. The relationships between different items were estimated by measuring Cronbach’s α coefficient. Split-half reliability, a subtype of internal consistency reliability, was assessed by computing the Guttman split-half coefficient. Validity was assessed by the receiver operating characteristic (ROC) curve, sensitivity, specificity, positive predictive value, and negative predictive value. SPSS 18.0 (SPSS Inc., Chicago, IL, USA) and MedCalc 12.5.0.0 (MedCalc Software, Mariakerke, Belgium) were used for the statistical analysis. A 2-sided P value < 0.05 was considered statistically significant.

Ethics statement
The patients were informed regarding this study, and written informed consent was obtained from all participants prior to enrollment. The study protocol was approved by the institutional review board of Severance Hospital (ref: 4-2014-0280) and Gangnam Severance Hospital (ref: 3-2014-0086).

RESULTS
Development of the K-LANSS
Though there were no serious linguistic problems during the LANSS pain scale translation, the authors found some minor discrepancies, which could be resolved by cross-cultural adaptation. First, shades of meaning exist between Korean and English when people answer the question by ‘Yes’ or ‘No’. In the Korean language people answer ‘Yes’ or ‘No’ in the place of the questioner. Therefore, the ‘Yes’-‘No’ order of answer is more familiar to the Korean user. The ‘No’-‘Yes’ order of answer in the original LANSS pain scale was modified to a ‘Yes’-‘No’ order. In addition, most native Koreans consider skin tone to be of a yellow hue, and do not use the expression ‘pink skin.’ Therefore, the second item in the first section of the LANSS, “looking more red or pink” was revised to “looking more red.”
Clinical study for reliability and validity of the K-LANSS
A total of 213 patients eligible for inclusion in the study were evaluated, of which 113 were diagnosed with neuropathic pain, and 100 with nociceptive pain (Table 1). There were no significant differences of socio-demographic and clinical characteristics between the neuropathic pain and nociceptive pain groups except duration of pain, which was shorter in the neuropathic pain group (Table 2).

The mean overall score of the K-LANSS pain scale attained from the neuropathic and nociceptive pain groups was 15.3 ± 6.5 and 3.3 ± 3.8, respectively, with significantly higher scores in the neuropathic pain group (P < 0.001). Cronbach’s α coefficient for assessing internal consistency of the whole K-LANSS was 0.815 (Table 3), and the Guttman split-half coefficient was 0.800.

The ROC curve of the K-LANSS pain scale is shown in Fig. 2. The area under the ROC curve (AUC) was 0.928 with a 95% confidence interval (CI) of 0.885-0.959 (P < 0.001). When the cut-off value of the original version, ≥ 12, was applied, the sensitivity was 72.6% (95% CI, 63.4-80.5), specificity was 98.0% (95% CI, 93.0-99.8), and the positive (PPV) and negative predictive values (NPV) were 98% and 76%, respectively (Table 4). The best cut-off point obtained by ROC curve analysis was 7, and the Youden index was 0.742. Corresponding to this point, sensitivity was 91.2% (95% CI, 84.3-95.7), specificity was 83.0% (95% CI, 74.2-89.8), and PPV and NPV were 86% and 89% respectively (Table 4). The kappa value was 0.694 (P < 0.001) which was computed for valuation of the concordance between clinical diagnosis and the diagnosis from the K-LANSS pain scale.

![Fig. 2. Receiver operating characteristic curve for neuropathic pain presence. Area under the curve was 0.928.](http://jkms.org)

### Table 2. Socio-demographic and clinical characteristics

| Parameters                      | Neuropathic (n = 113) | Nociceptive (n = 100) | P value |
|---------------------------------|-----------------------|-----------------------|---------|
| Age (yr)                        | 57.2 ± 15.6           | 54.8 ± 17.1           | 0.272   |
| Gender (male/female)            | 42/71                 | 32/68                 | 0.429   |
| NRS pain score (0-10)           | 6.6 ± 1.7             | 6.5 ± 1.7             | 0.577   |
| Duration of pain (months)       | 24.4 ± 28.4           | 41.0 ± 73.8           | 0.029*  |
| Occupation (No. of patients)    |                       |                       | 0.603   |
| Employee                        | 18 (16%)              | 24 (24%)              |         |
| Retired                         | 10 (9%)               | 4 (4%)                |         |
| Self-employed                   | 11 (10%)              | 8 (8%)                |         |
| Home-maker                      | 47 (42%)              | 43 (43%)              |         |
| Student                         | 4 (3%)                | 3 (3%)                |         |
| Employer                        | 0 (0%)                | 11 (11%)              |         |
| Unemployed                      | 17 (15%)              | 11 (11%)              |         |
| Others                          | 6 (5%)                | 6 (6%)                |         |
| Educational level (No. of patients) |                   |                       | 0.571   |
| Elementary                      | 24 (21%)              | 20 (20%)              |         |
| Middle                          | 13 (12%)              | 12 (12%)              |         |
| High                            | 41 (36%)              | 28 (28%)              |         |
| University                      | 27 (24%)              | 33 (33%)              |         |
| Postgraduate                    | 8 (7%)                | 7 (7%)                |         |

Values are mean ± standard deviation or number of patients (%). *P < 0.05. NRS, numeric rating scale.

### Table 3. Cronbach’s α coefficients and exploratory factor analysis of the Korean version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale

| Factors                        | Cronbach’s α coefficient | Cronbach’s α coefficient if the item is excluded | Factor loading |
|--------------------------------|--------------------------|-----------------------------------------------|----------------|
| The whole K-LANSS               |                           |                                               | 0.815          |
| Symptoms                       |                           |                                               |                |
| Dysesthesia                    | 0.812                    | 0.546                                         |                |
| Autonomic                      | 0.802                    | 0.621                                         |                |
| Evoked                         | 0.809                    | 0.586                                         |                |
| Paroxysmal                     | 0.786                    | 0.708                                         |                |
| Thermal                        | 0.793                    | 0.674                                         |                |
| Signs                          |                           |                                               |                |
| Alldynia                       | 0.759                    | 0.844                                         |                |
| Hyperalgesia                   | 0.766                    | 0.815                                         |                |

K-LANSS, Korean version of the Leeds Assessment of Neuropathic Symptoms and Signs.
DISCUSSION

This study demonstrated that the K-LANSS pain scale has good reliability and validity as a neuropathic pain assessment tool. To the best of our knowledge, this is the first attempt to translate and study the validity of a neuropathic pain screening questionnaire in Korea. Although the Korean Neuropathic Pain Questionnaire for neuropathic pain screening and grading has already been developed in Korea (16), its specificity was somewhat low according to a pilot study, and it has not yet gained much domestic acceptance.

Neuropathic pain is known to impair quality of life and is more costly to treat than other pain conditions (17). Therefore, the identification of neuropathic pain is a critical first step in designing appropriate therapeutic strategies and improving the quality of life for patients. However, complicated and variable clinical manifestations of neuropathic pain make the diagnosis quite challenging, as the symptoms often appear differently at each stage of the disease, and lesions of the somatosensory nervous system are difficult to detect (2, 18). Against this backdrop, many questionnaires for neuropathic pain screening have been introduced, and the LANSS pain scale developed by Bennett is a very useful test that provides immediate clinical information and helps differentiate nociceptive pain from neuropathic pain (4).

In this study, internal consistency analysis was used to assess the reliability of the K-LANSS. The Cronbach’s α value of the K-LANSS was 0.815, indicating satisfactory internal consistency. This value exceeds the values for the Spanish (0.68) (6), Brazilian Portuguese (0.67) (8), and Portuguese versions (0.78) (9) and is consistent with the values for the Turkish (0.841) (5) and Chinese Mandarin versions (0.824) (10). After additional analysis using the split-half method, the Guttman split-half coefficient value was 0.800, greater than the suggested cut-off of 0.7 and equivalent to the value of the Chinese Mandarin version (0.842) (10). Performing appropriate interventional management or beginning administration of medicine is general clinical practice in the hospitals to which the authors belong, depending on the diagnosis of the patients visiting the outpatient clinic. Therefore, the test-retest findings used to assess the consistency of a measure from one time to another could have been affected by individual patient treatments. Thus, test-retest analysis was not carried out.

Regarding validity, the AUC provides a critical estimate of the expected accuracy of a test (19). In our study, the AUC of the K-LANSS was 0.928, using expert clinical diagnosis as the gold standard. In the original version of the LANSS pain scale, the sensitivity and specificity were 83% and 87% respectively, and the best cut-off value for discrimination of neuropathic pain was 12. The sensitivity and specificity in the K-LANSS using the original cut-off value of 12 were 72.6% and 98.0%, respectively, representing slightly lower sensitivity and slightly higher specificity than the original version. When using a cut-off value of 7, which is the optimal cut-off value obtained by making a graph of the ROC curve in the K-LANSS, the sensitivity and specificity were 91.2% and 83.0%, respectively. The kappa value, an indicator of the diagnostic concordance rate, was 0.694, higher than the 0.65 value of the original version. In conclusion, these results suggest that the K-LANSS displays high validity.

In the present study, patients with mixed pain were excluded. In cases with symptoms such as radiculopathy and nerve entrapment with pain presentation caused by neuropathic and/or nociceptive mechanisms, a definite diagnosis of pain with only a neuropathic component was required for inclusion in the neuropathic pain group. We excluded patients with mixed pain presentation, because there was no way to distinguish pain types, and no mixed pain group was used in the original study.

There was some concern that the use of a cutting needle such as 23-gauge needle may cause bleeding when the LANSS pain scale was applied to patients (20). However, no patients with injury by the 23-gauge needle examination were found, and we believe the pinprick test of this scale is safe.

The present instrument is simple, easy, and less time-consuming for both patients and physicians. Therefore, it may be useful for patients with neuropathic pain who have poor patient compliance on questionnaires, and it can be a readily employable screening tool for physicians who find it difficult to conduct a comprehensive assessment.

This study has some limitations. First, although patients with neuropathic and/or nociceptive pain also visit departments of neurology, orthopedics, and neurosurgery for diagnosis and treatment of disease, we recruited patients who visited the outpatient department for pain management. However, the authors believe that the findings of the present study are generalizable, because 2 tertiary university hospitals were involved in the research. Nevertheless, this study could have more representation power if it was a multicenter study including a primary care clinic. In addition, further research is needed for more definitive results in order to make conclusions regarding epidemiologic information. Second, because there are no other Korean versions of questionnaires for screening of neuropathic pain except for the K-LANSS, we could not test convergent validity. We expect that the findings of this study will help with the development of Korean versions of other neuropathic pain questionnaires. Third, the committee in this study consisted of forward translators, back translators, 5 pain specialists, but no linguistic specialists. Although supervision of a linguist would have made the K-LANSS more reliable and valid, the authors deliberated on linguistic features and cultural background for development of the K-LANSS. Before all, because in each item of the original LANSS the example follows main question, it suggests simple and typical expression describing applicable pain. There-
fore, the authors suppose this limitation not so crucial to the findings of this study in spite of the exclusion of linguistic specialists in the committee during translation and adaptation.

In conclusion, this study confirmed that the K-LANSS is a useful, reliable, and valid questionnaire for discrimination of neuropathic pain from nociceptive pain. The K-LANSS is the first Korean version of a screening questionnaire for patients with neuropathic pain. We hope that the K-LANSS will not only come into widespread use as a screening tool, but also provide objective information for the study of neuropathic pain with support from the results of this study.

ACKNOWLEDGMENTS

The authors would like to thank to Dr. M. I. Bennett (School of Medicine, Leeds Institute of Health Sciences, University of Leeds) for permitting the use of the LANSS pain scale and for his encouragement.

DISCLOSURE

The authors have no conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conception and coordination of the study: Park C, Kim DH. Design of ethical issues: Park C, Kim DH. Acquisition of data: Park C, Lee YW, Yoon DM, Nam DJ, Kim DH. Data review: Lee YW, Yoon DM, Kim DW. Statistical analysis: Park C, Kim DW, Kim DH. Manuscript preparation: Park C, Nam DJ, Kim DH. Manuscript approval: all authors.

ORCID

Cholhee Park http://orcid.org/0000-0001-7247-9469
Youn-Woo Lee http://orcid.org/0000-0002-3056-9826
Duck Mi Yoon http://orcid.org/0000-0001-9215-4389
Do Wan Kim http://orcid.org/0000-0002-4176-2082
Da Jeong Nam http://orcid.org/0000-0001-9136-5272
Do-Hyeong Kim http://orcid.org/0000-0003-2018-8090

REFERENCES

1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, Treede RD. A new definition of neuropathic pain. Pain 2011; 152: 2204-5.
2. Haanpää M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G, Hansson P, Haythornthwaite JA, Iannetti GD, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011; 152: 14-27.
3. Jones RC 3rd, Backonja MM. Review of neuropathic pain screening and assessment tools. Curr Pain Headache Rep 2013; 17: 363.
4. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001; 92: 147-57.
5. Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M. Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. J Pain 2004; 5: 427-32.
6. Pérez C, Gálvez R, Insauti J, Bennett M, Ruiz M, Rejas J; Group for the study of Spanish validation of LANSS. Linguistic adaptation and Spanish validation of the LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) scale for the diagnosis of neuropathic pain. Med Clin (Barc) 2006; 127: 485-91.
7. Hallström H, Norbrink C. Screening tools for neuropathic pain: can they be of use in individuals with spinal cord injury? Pain 2011; 152: 772-9.
8. Schestatsky P, Félix-Torres V, Chaves ML, Câmara-Ehlers B, Mucenic T, Caumo W, Nascimento O, Bennett MI. Brazilian Portuguese validation of the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale in the Portuguese population. Pain Pract 2014; 14: 620-4.
9. Barbosa M, Bennett MI, Verissimo R, Carvalho D. Cross-cultural psychometric assessment of the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale in the Portuguese population. Pain Med 2011; 12: 1544-50.
10. Li J, Feng Y, Han J, Fan B, Wu D, Zhang D, Du D, Li H, Lim J, Wang J, et al. Linguistic adaptation, validation and comparison of 3 routinely used neuropathic pain questionnaires. Pain Physician 2012; 15: 179-86.
11. Bennett MI, Bouhassira D. Epidemiology of neuropathic pain: can we use the screening tools? Pain 2007; 132: 12-3.
12. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000; 25: 3186-91.
13. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417-32.
14. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmiäko T, Serra J. Neuropathic pain: re-definition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-5.
15. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007; 60: 34-42.
16. Yun DJ, Oh J, Kim BJ, Lim JG, Bae JS, Jeong D, Joo IS, Park MS, Kim BJ. Development of Korean Neuropathic Pain Questionnaire for neuropathic pain screening and grading: a pilot study. J Korean Neurol Assoc 2012; 30: 15-25.
17. O’Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009; 27: 95-112.
18. Schestatsky P, Gerchman F, Valls-Solé J. Neurophysiological tools for small fiber assessment in painful diabetic neuropathy (comment letter). Pain Med 2009; 10: 601; author reply 2.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 857-45.
20. Backonja MM. Need for differential assessment tools of neuropathic pain and the deficits of LANSS pain scale. Pain 2002; 98: 229-30; author reply 30-1.
THE LANSS PAIN SCALE (LANSS 통증척도)
Leeds Assessment of Neuropathic Symptoms and Signs

이름 __________________ 날짜 ___________________

A. 통증설문
· 지난 1주일 동안 귀하의 통증이 어떻게 느껴졌는지 생각해 보십시오.
· 귀하가 느낀 통증을 설명하는 표현에 답을 해 주십시오.

1) 귀하가 느끼는 통증은 피부의 이상하고 불쾌한 느낌입니까?
따끔거리거나 저리거나 핀 또는 바늘에 찔리는 느낌을 말합니다.
a) 예 - 이러한 느낌이 매우 자주 듭니다 ...........................................................(5)
b) 아니오 - 내 통증은 이러한 느낌이 아닙니다 ..................................................(0)

2) 귀하가 느끼는 통증으로 인하여 통증 부위의 피부가 정상일 때와 다른 외관상 변화를 보였습니까?
통증 부위의 피부가 얼룩덜룩 하거나 평소보다 색깔이 더 붉어지는 경우를 말합니다.
a) 예 - 통증과 함께 정상일 때와 다른 피부의 외관상 변화가 있었습니다 ................(5)
b) 아니오 - 통증이 피부 색깔 변화에 영향을 미치지 않았습니다 .............................(0)

3) 귀하가 느끼는 통증 때문에 피부에 뭔가가 닿을 때, 평소보다 지나치게 민감합니까?
가볍게 만졌을 때 불쾌한 느낌이 있거나, 꽉 쳤을 때 점점 아픈 느낌이 드는 경우를 말합니다.
a) 예 - 통증 부위의 피부가 평소보다 지나치게 민감합니다 ....................................(3)
b) 아니오 - 통증으로 인해 그 부위의 피부가 민감하지 않습니다 ..............................(0)

4) 귀하가 느끼는 통증은 아무 이유 없이 갑자기 불쑥 발생합니까?
전기의 감전된 느낌이나 물 뜨이 뜨끈한 느낌 또는 터질 듯이 아픈 느낌을 말합니다.
a) 예 - 이러한 느낌이 매우 자주 듭니다 .................................................................(2)
b) 아니오 - 내 통증은 이러한 느낌이 아닙니다 .........................................................(0)

5) 귀하가 느끼는 통증 부위의 피부온도가 평소와 달리 변한 것 같이 느껴졌습니까?
피부가 뜨겁거나 써는 듯한 느낌을 말합니다.
a) 예 - 이러한 느낌이 매우 자주 듭니다 .................................................................(1)
b) 아니오 - 내 통증은 이러한 느낌이 아닙니다 .........................................................(0)

이 통증척도는 통증신호를 전달하는 신경들이 정상적으로 기능하는지 알아보기 위한 것으로 답변에 따라 치료방법이 달라지므로 잘 읽고 답해주시기 바랍니다.

Appendix 1. The Korean version of the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale.
B. 감각검사
피부 민감도는 통증 부위와 통증이 없는 인접 부위, 또는 반대편 동일 부위를 비교하여 이질통이 나타나거나 침통각역치가 변화하는 것으로 검사합니다.

1) 이질통
탈지면으로 먼저 통증이 없는 부위를 가볍게 문질러 감각을 확인한 후, 통증 부위도 가볍게 문질러 감각을 확인합니다. 비통증 부위에는 정상적인 감각이 느껴지고, 통증 부위에는 아프거나 불쾌한 느낄거리거나 메스꺼운 느낌이 들면 이질통이 있는 것입니다.

   a) 예 - 통증부위에 이질통이 느껴집니다 ...........................................................(5)
   b) 아니오 - 통증 부위, 비통증 부위 모두 정상 감각이 느껴집니다 ........................(0)

2) 침통각역치의 변화
23 게이지(파랑색) 주사 바늘을 2 mL 주사기에 끼우고 먼저 비통증 부위에 가볍게 갖다 대어 반응을 확인하고, 이후 통증 부위에도 같은 방법으로 시행하여 두 부위의 반응을 비교함으로써 침통각역치를 확인합니다.

비통증 부위에는 따끔거리는 느낌이 나고, 통증 부위에는 다른 느낌, 예를 들어 느낌이 약해졌거나, 무언 느낌이 들거나(침통각역치 상승) 아주 아프면(침통각역치 하락) 침통각역치의 변화가 있는 것 입니다.

따끔한 느낌이 비통증 부위와 통증 부위 둘 다 느껴지지 않으면, 바늘 쪽에 좀 더 무게를 가하여 다시 확인합니다.

   a) 예 - 통증 부위에 침통각역치의 변화가 있습니다 ...........................................(3)
   b) 아니오 - 통증 부위, 비통증 부위 모두 같은 감각이 느껴집니다 ........................(0)

점수계산: 각 항목의 괄호 안의 점수를 합산하여 총점을 구합니다.
※ 총점(최대 24점): __________

점수 <12점: 신경병성 기전이 환자의 통증과 연관되지 않은 것으로 보입니다.
점수 ≥12점: 신경병성 기전이 환자의 통증과 연관된 것으로 보입니다.

출처: Bennett, M, The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and sign. Pain 2001; 92: 147–157.